BACKGROUND: The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a characteristic rash. Effective biomarkers will be required to monitor disease progression, guide the choice of therapeutic intervention strategies and evaluate their efficacies. To address this we have evaluated several biomarkers of disease in a lethal mousepox model. METHODS: The efficacy of a single dose of a hexadecyloxypropyl ester of cidofovir (CMX001) at 20, 25 and 30 mg/kg doses administered on days 4, 5, 6 and 7 post-infection was evaluated in A/Ncr mice intranasally infected with low doses of ectromelia virus (<20 plaque-forming units). Mice were monitored for weight loss, blood interferon-gamma levels, alanine aminotransferase (ALT), aspartate aminotransferase, viral DNA copies and neutrophilia levels to stage disease progression. RESULTS: We have used these biomarkers to establish the optimal dosing regimen for treatment and reveal that a single dose of 25 mg/kg of CMX001 can be efficacious at treating lethal mousepox when administered on days 4 or 5 post-infection. This dose significantly reduces ALT, interferon-gamma and DNA copies found in the blood of infected animals. CONCLUSIONS: A single dose regimen of CMX001 is efficacious at treating mousepox. Disease progression and antiviral efficacy can be monitored using several biomarkers that could readily be used in the case of a human monkeypox or smallpox outbreak.
BACKGROUND: The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a characteristic rash. Effective biomarkers will be required to monitor disease progression, guide the choice of therapeutic intervention strategies and evaluate their efficacies. To address this we have evaluated several biomarkers of disease in a lethal mousepox model. METHODS: The efficacy of a single dose of a hexadecyloxypropyl ester of cidofovir (CMX001) at 20, 25 and 30 mg/kg doses administered on days 4, 5, 6 and 7 post-infection was evaluated in A/Ncr mice intranasally infected with low doses of ectromelia virus (<20 plaque-forming units). Mice were monitored for weight loss, blood interferon-gamma levels, alanine aminotransferase (ALT), aspartate aminotransferase, viral DNA copies and neutrophilia levels to stage disease progression. RESULTS: We have used these biomarkers to establish the optimal dosing regimen for treatment and reveal that a single dose of 25 mg/kg of CMX001 can be efficacious at treating lethal mousepox when administered on days 4 or 5 post-infection. This dose significantly reduces ALT, interferon-gamma and DNA copies found in the blood of infected animals. CONCLUSIONS: A single dose regimen of CMX001 is efficacious at treating mousepox. Disease progression and antiviral efficacy can be monitored using several biomarkers that could readily be used in the case of a human monkeypox or smallpox outbreak.
Authors: R Mark Buller; Gelita Owens; Jill Schriewer; Lora Melman; James R Beadle; Karl Y Hostetler Journal: Virology Date: 2004-01-20 Impact factor: 3.616
Authors: Stephanie L Ciesla; Julissa Trahan; W Brad Wan; James R Beadle; Kathy A Aldern; George R Painter; Karl Y Hostetler Journal: Antiviral Res Date: 2003-08 Impact factor: 5.970
Authors: Debra C Quenelle; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Earl R Kern Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Karen L Denzler; Jill Schriewer; Scott Parker; Chas Werner; Hollyce Hartzler; Ed Hembrador; Trung Huynh; Susan Holechek; R M Buller; Bertram L Jacobs Journal: Vaccine Date: 2011-10-05 Impact factor: 3.641
Authors: Julie Dyall; Reed F Johnson; Svetlana Chefer; Christopher Leyson; David Thomasson; Jurgen Seidel; Dan R Ragland; Russell Byrum; Catherine Jett; Jennifer A Cann; Marisa St Claire; Elaine Jagoda; Richard C Reba; Dima Hammoud; Joseph E Blaney; Peter B Jahrling Journal: J Virol Date: 2017-10-13 Impact factor: 5.103
Authors: Scott Parker; Akbar M Siddiqui; Christina Oberle; Ed Hembrador; Randall Lanier; George Painter; Alice Robertson; R Mark Buller Journal: Virology Date: 2008-12-18 Impact factor: 3.616
Authors: Scott Parker; Nanhai G Chen; Scott Foster; Hollyce Hartzler; Ed Hembrador; Dennis Hruby; Robert Jordan; Randall Lanier; George Painter; Wesley Painter; John E Sagartz; Jill Schriewer; R Mark Buller Journal: Antiviral Res Date: 2012-02-18 Impact factor: 10.103
Authors: Haifeng Song; Krisztina Janosko; Reed F Johnson; Jing Qin; Nicole Josleyn; Catherine Jett; Russell Byrum; Marisa St Claire; Julie Dyall; Joseph E Blaney; Gerald Jennings; Peter B Jahrling Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240